 The results showed that the overall safety of the treatment was satisfactory and the lesions produced by the HIFU shots in the nodule were precise. This pilot study was extended to a clinical trial where patients with a benign thyroid nodule were treated. Twenty-one patients were treated in this study versus 11 controls. No serious adverse events SAE have occurred. A patient with a toxic thyroid nodule was also treated with the HIFU device Theraclion, France. The treatment was well tolerated and biologic euthyroidism was achieved at 3 months TSH, 1.91 mIUL and was maintained at 6, 12, and 18 months. At 12 and 18 months, the treated nodule was barely seen as a nonvascularized hypoechoic scar. Thyroid scintigraphy showed a recovery of the thyroid iodine uptake. 